Study on the therapeutic efficacy of conventional crude drug products 'Panaparl tablets' comprising of angelica root, cnidium rhizome, peony root, rehmannia root, etc. on cognitive impairment

Study on the therapeutic efficacy of conventional crude drug products 'Panaparl tablets' comprising of angelica root, cnidium rhizome, peony root, rehmannia root, etc. on cognitive impairment - Study on the therapeutic efficacy of conventional crude drug products 'Panaparl tablets' on cognitive impairment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028701

Enrollment

Registered

2017-10-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment and early Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Forgetfulness Impairment of attention and/or concentration

Exclusion criteria

Exclusion criteria: Psychiatric disorders like visual and auditory hallucinations Focal symptoms like hemiparesis and aphasia

Design outcomes

Primary

Measure	Time frame
Using RBANS neuropsychological test, the amnesic patients were classified into "forgetful group" with a total score of 30 to 45 and "pre-dementia group" less than 25. Before and after treatment with conventional crude drug products 'Panaparl tablets' for 3 months, the RBANS neuropsychological tests are done to elucidate its therapeutic effects on the cognitive function owing to its improvement of the cerebral blood flow.	—

Measure

Time frame

Using RBANS neuropsychological test, the amnesic patients were classified into "forgetful group" with a total score of 30 to 45 and "pre-dementia group" less than 25. Before and after treatment with conventional crude drug products 'Panaparl tablets' for 3 months, the RBANS neuropsychological tests are done to elucidate its therapeutic effects on the cognitive function owing to its improvement of the cerebral blood flow.

—

Countries

Japan

Contacts

Public ContactTakahiro Ueda

Zaiseido Pharmaceutical Co., Ltd. Academic department

t-ueda@zaiseido.co.jp073-472-3111

Outcome results